IMNM

MKT CAP:$2B

Immunome, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$23.76+$2.94 (+14.12%)

Apr 24, 2026

Company Details

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capa...

CEO

Clay Siegall

IPO Date

Oct 2, 2020

Website

immunome.com

Key Metrics TTM

Revenue

$7M

-23.2% YoY

Net Income

-$212M

EPS (Diluted)

-$2.43

Free Cash Flow

-$201M

Revenue / Share

$0.08

Gross Margin

-630.3%

Operating Margin

-3084.8%

Net Margin

-3060.0%

FCF Margin

-2890.1%

P/S

298.6x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 3, 2026

$7M-23.2%EPS -$2.43

Q4 2025

Mar 3, 2026

$0-100.0%EPS -$0.76

Q3 2025

Nov 6, 2025

$0-100.0%EPS -$0.65

Q2 2025

Aug 6, 2025

$4M+69.8%EPS -$0.50

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$12M
Q2 22	$0	$0	-$9M
Q3 22	$0	$0	-$9M
Q4 22	$0	$0	-$8M
Q1 23	$2M	-$2M	-$4M
Q2 23	$4M	-$1M	-$6M
Q3 23	$4M	$3M	-$5M
Q4 23	$4M	$4M	-$95M
Q1 24	$1M	$1M	-$132M
Q2 24	$2M	$2M	-$40M
Q3 24	$3M	$3M	-$51M
Q4 24	$3M	$3M	-$83M
Q1 25	$3M	$3M	-$45M
Q2 25	$4M	$3M	-$46M
Q3 25	$0	-$49M	-$60M
Q4 25	$0	-$776.0K	-$63M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	876.7x	—
Q2 23	312.8x	—
Q3 23	203.4x	—
Q4 23	147.9x	—
Q1 24	163.4x	—
Q2 24	192.2x	—
Q3 24	204.6x	—
Q4 24	229.2x	—
Q1 25	189.5x	—
Q2 25	164.6x	—
Q3 25	214.1x	—
Q4 25	298.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$6M	-$6M
Q2 22	-$8M	-$8M
Q3 22	-$8M	-$8M
Q4 22	-$7M	-$7M
Q1 23	$24M	$24M
Q2 23	-$6M	-$6M
Q3 23	-$9M	-$9M
Q4 23	-$17M	-$18M
Q1 24	-$11M	-$13M
Q2 24	-$23M	-$26M
Q3 24	-$34M	-$36M
Q4 24	-$42M	-$43M
Q1 25	-$53M	-$57M
Q2 25	-$49M	-$50M
Q3 25	-$41M	-$42M
Q4 25	-$48M	-$52M

Capital Expenditures

Quarter	CapEx
Q1 22	$6.0K
Q2 22	$170.0K
Q3 22	$0
Q4 22	$72.0K
Q1 23	$106.0K
Q2 23	$340.0K
Q3 23	$36.0K
Q4 23	$349.0K
Q1 24	$2M
Q2 24	$2M
Q3 24	$2M
Q4 24	$1M
Q1 25	$4M
Q2 25	$905.0K
Q3 25	$1M
Q4 25	$4M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+199.1%
Q2 22	—	+55.5%
Q3 22	—	+10.5%
Q4 22	—	-0.7%
Q1 23	—	-41.4%
Q2 23	—	+12.4%
Q3 23	—	-3.9%
Q4 23	—	+1164.7%
Q1 24	-56.5%	+1850.7%
Q2 24	-44.5%	+322.2%
Q3 24	-18.4%	+551.8%
Q4 24	-28.4%	-13.0%
Q1 25	+184.4%	-64.3%
Q2 25	+69.8%	+19.2%
Q3 25	-100.0%	+12.6%
Q4 25	-100.0%	-26.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$1M	—
Q3 22	$1M	—
Q4 22	$1M	—
Q1 23	$1M	51.8%
Q2 23	$1M	24.2%
Q3 23	$1M	30.4%
Q4 23	$3M	75.4%
Q1 24	$2M	209.8%
Q2 24	$3M	136.5%
Q3 24	$5M	168.1%
Q4 24	$5M	199.8%
Q1 25	$6M	194.9%
Q2 25	$5M	133.2%
Q3 25	$7M	—
Q4 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$8M	$4M	—
Q2 22	$6M	$3M	—
Q3 22	$5M	$3M	—
Q4 22	$4M	$4M	—
Q1 23	$4M	$3M	—
Q2 23	$6M	$4M	—
Q3 23	$4M	$4M	—
Q4 23	$10M	$8M	—
Q1 24	$15M	$6M	—
Q2 24	$29M	$7M	—
Q3 24	$37M	$10M	—
Q4 24	$48M	$10M	—
Q1 25	$37M	$11M	—
Q2 25	$40M	$10M	—
Q3 25	$49M	$11M	—
Q4 25	$51M	—	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$43M	$0	$43M
Q2 22	$35M	$0	$35M
Q3 22	$27M	$0	$27M
Q4 22	$20M	$0	$20M
Q1 23	$44M	$0	$44M
Q2 23	$38M	$0	$38M
Q3 23	$91M	$0	$91M
Q4 23	$99M	$39M	$138M
Q1 24	$270M	$40M	$310M
Q2 24	$165M	$113M	$278M
Q3 24	$156M	$85M	$240M
Q4 24	$143M	$74M	$217M
Q1 25	$258M	$60M	$317M
Q2 25	$144M	$124M	$268M
Q3 25	$273M	$0	$273M
Q4 25	$653M	$0	$653M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	12M	+1.6%	+13.9%
Q2 22	12M	+0.0%	+5.9%
Q3 22	12M	+0.0%	+1.6%
Q4 22	12M	+0.0%	+1.6%
Q1 23	12M	+0.4%	+0.5%
Q2 23	12M	+0.1%	+0.6%
Q3 23	12M	+0.0%	+0.6%
Q4 23	22M	+79.9%	+81.0%
Q1 24	10M	-53.0%	-15.4%
Q2 24	60M	+481.4%	+391.4%
Q3 24	60M	+0.4%	+393.4%
Q4 24	63M	+4.2%	+185.7%
Q1 25	79M	+26.6%	+670.3%
Q2 25	87M	+9.6%	+45.2%
Q3 25	88M	+1.1%	+46.1%
Q4 25	87M	-0.7%	+39.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	39
Q2 22	$0	39
Q3 22	$0	39
Q4 22	$0	37
Q1 23	$63.9K	37
Q2 23	$115.2K	37
Q3 23	$96.4K	37
Q4 23	$69.6K	55
Q1 24	$18.7K	55
Q2 24	$43.0K	55
Q3 24	$52.9K	55
Q4 24	$23.2K	118
Q1 25	$24.8K	118
Q2 25	$34.0K	118
Q3 25	$0	118
Q4 25	$0	200K

Revenue / Employee